Furiex Pharmaceuticals Inc  

(Public, NASDAQ:FURX)   Watch this stock  
Find more results for FURX
-1.88 (-2.44%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 74.38 - 78.10
52 week 32.01 - 121.97
Open 76.98
Vol / Avg. 199,354.00/235,423.00
Mkt cap 813.01M
P/E     -
Div/yield     -
EPS -2.98
Shares 10.81M
Beta 1.85
Inst. own 67%
May 22, 2014
Furiex Pharmaceuticals Inc Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
May 8, 2014
Q1 2014 Furiex Pharmaceuticals Inc Earnings Conference Call - 9:00AM EDT - Add to calendar
May 7, 2014
Q1 2014 Furiex Pharmaceuticals Inc Earnings Release - 4:00PM EDT - Add to calendar
Mar 12, 2014
Q4 2013 Furiex Pharmaceuticals Inc Earnings Conference Call
Mar 11, 2014
Q4 2013 Furiex Pharmaceuticals Inc Earnings Release
Mar 3, 2014
Furiex Pharmaceuticals Inc at Cowen Health Care Conference
Feb 4, 2014
Furiex Pharmaceuticals Inc Furiex Pharmaceuticals Announces Positive Top-Line Results of Two Pivotal Phase III Clinical Trials of Eluxadoline in Patients with IBS-d
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -49.49% -41.79%
Operating margin -35.31% -34.42%
EBITD margin - -34.34%
Return on average assets -27.43% -32.39%
Return on average equity -127.16% -105.90%
Employees 24 -
CDP Score - -


Suite 150, 3900 Paramount Parkway
United States - Map
+1-919-4567800 (Phone)
+1-302-5313150 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company´┐Żs product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. Priligy (dapoxetine) is a drug developed for the on-demand treatment of premature ejaculation (PE). Dapoxetine is a short-acting, selective serotonin reuptake inhibitor (SSRI) designed to be taken only when needed one to three hours before sexual intercourse is anticipated rather than every day. Nesina (alogliptin) is a drug for the oral treatment of type 2 diabetes (T2D). In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V.

Officers and directors

Fredric N. Eshelman Pharm.D. Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
June S. Almenoff M.D., Ph.D. President, Chief Medical Officer, Principal Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Sailash Patel Chief Financial Officer and Vice President - Strategic Development
Age: 55
Bio & Compensation  - Reuters
Paul S. Covington M.D. Senior Vice President - Clinical Development and Operations
Age: 57
Bio & Compensation  - Reuters
Gail F. McIntyre Ph.D. Senior Vice President - Research
Age: 50
Bio & Compensation  - Reuters
Peter B. Corr Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Wendy L. Dixon Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Stephen W. Kaldor Ph.D. Independent Director
Age: 51
Bio & Compensation  - Reuters